ArticleApplied microbiology and biotechnology2025
Extracellular peptide production in Escherichia coli by inducible downregulation of lipoprotein Lpp via MicL sRNA.
Article in Applied microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite its many benefits, Escherichia coli only poorly secretes recombinant proteins and peptides into the medium. This complicates downstream processing and notably contributes to the production costs of biopharmaceuticals. The permeability of production strains can be increased by deletion of the lpp gene, coding for Braun's lipoprotein Lpp. Consequently, the outer membrane (OM) is destabilized, and periplasmic recombinant proteins/peptides can leak out of the cell into the cultivation medium. However, we observed poor process performance during C-limited fed-batch cultivations in bioreactors when production strains with lpp knockout were cultivated. In this study, we developed an inducible system for in-process Lpp downregulation (knockdown) in E. coli with the goal to facilitate the release of the periplasmic recombinant fusion peptide CASPON-SST into the cultivation medium. By plasmid-based overexpression of MicL sRNA, we were able to efficiently inhibit Lpp synthesis and increase the OM permeability of our production strains. With this approach, we were able to achieve the secretion of 80-100% of all peptide and increased production capacities. The system was further optimized by utilizing different promoter systems to induce peptide and MicL expression separately in order to coordinate them. We report here for the first time the extracellular production of a recombinant peptide by inducible downregulation of Lpp via MicL sRNA during C-limited fed-batch cultivations. By utilizing a flexible system for Lpp knockdown, potential drawbacks of lpp knockout can be counteracted, thus making our approach a valuable tool for the in-process adaptation of OM permeability in production hosts. KEY POINTS: • Lpp can be downregulated on mRNA level by MicL sRNA overexpressed during fed-batch. • Recombinant peptides can leak out of the periplasm when Lpp is downregulated. • Leakiness and outer membrane permeability must be distinguished.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.